Medical specialists from Japan tagged as investigators in clinical trials studying Liver Cirrhosis, Biliary

Total 20 results

Atsumasa Komori
Seen in:
- Nagasaki, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Atsushi Tanaka
Seen in:
- Tokyo, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis
Fumihiko Kusano
Seen in:
- Ibaraki, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
Conditions:
- Pruritus
Kazuhito Kawata
Seen in:
- Shizuoka, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis
Kazuo Notsumata
Seen in:
- Fukui, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Keiji Tsuji
Seen in:
- Hiroshima, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis
Koichi Takaguchi
Seen in:
- Kagawa, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
- Pruritus;
- Hepatitis B
Kunihiko Tsuji
Seen in:
- Hokkaido, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis
Masanori Abe
Seen in:
- Ehime, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis
Masanori Atsukawa
Seen in:
- Tokyo, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
Michio Imamura
Seen in:
- Hiroshima, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT04954859 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis;
- Hepatitis B
Mikio Yanase
Seen in:
- Tokyo, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
Conditions:
- Pruritus;
- Cholestasis
Naohiro Kawamura
Seen in:
- Tokyo, GSK Investigational Site
Trials:
- NCT04167358 (Principal Investigator)
Conditions:
- Cholestasis
Naoki Hiramatsu
Seen in:
- Osaka, GSK Investigational Site
Trials:
- NCT04167358 (Principal Investigator)
Conditions:
- Cholestasis
Sawako Uchida
Seen in:
- Osaka, GSK Investigational Site
Trials:
- NCT04167358 (Principal Investigator)
Conditions:
- Cholestasis
Tadashi Namisaki
Seen in:
- Nara, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05630820 (Principal Investigator)
Conditions:
Takeji Umemura
Seen in:
- Nagano, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Tatehiro Kagawa
Seen in:
- Kanagawa, GSK Investigational Site
Trials:
- NCT04950127 (Principal Investigator)
- NCT04167358 (Principal Investigator)
- NCT05583344 (Principal Investigator)
Conditions:
Tomomi Okubo
Seen in:
- Chiba, GSK Investigational Site
Trials:
- NCT04167358 (Principal Investigator)
Conditions:
- Cholestasis
Yuichi Yamazaki
Seen in:
- Gunma, GSK Investigational Site
Trials:
- NCT04167358 (Principal Investigator)
Conditions:
- Cholestasis

Clinical Trials on Liver Cirrhosis, Biliary

University Health Network, Toronto

Unknown

Family Studies in Primary Biliary Cirrhosis (PBC)

Biliary Cirrhosis, Primary

Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
CymaBay Therapeutics, Inc.

Terminated

Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis (PBC)

Germany, United States, Canada, United Kingdom, Poland
University Health Network, Toronto

Unknown

Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary | Biliary Cirrhosis, Primary

Canada
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
Dr. Falk Pharma GmbH

Completed

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Germany
Instituto Nacional de Ciencias Medicas y Nutricion...

Unknown

Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders

Primary Biliary Cirrhosis

Mexico
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Benedetta Terziroli, MD
Intercept Pharmaceuticals; Vifor Pharma; Fondazione Epatocentro Ticino

Completed

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

Primary Biliary Cirrhosis

Switzerland

Medical specialists from Japan tagged as investigators in clinical trials studying Liver Cirrhosis, Biliary

Clinical Trials on Liver Cirrhosis, Biliary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations